Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.

The present invention provides a compound of Formula I: wherein R.sup.1 is hydrogen, F, or .sup.18F; and R.sup.2 is hydrogen, F, or .sup.18F; or a pharmaceutically acceptable salt thereof, provided that when R.sup.1 is .sup.18F then R.sup.2 is not .sup.18F, useful as a CGRP receptor antagonist for PET imaging.

##STR00001##

##STR00001##

Disclosed herein is a salt of formula I: where R.sup.1, X, n, R, R.sup.1, Y, m, p, q, Z and o are as defined herein. Also disclosed herein are methods of using said salts in chemical synthesis, such as to prepare compounds isotopically enriched in 18F for use in PET & imaging, as well as methods to make the compounds of formula I.

Provided are isotopically-labelled Trapidil derivatives useful for the treatment of Parkinson's disease and movement disorders associated with Parkinson's disease. The isotopically-labelled Trapidil derivatives include deuterated Trapidil derivatives. Additionally provided are combination therapies of isotopically-labelled Trapidil derivatives and additional therapeutic agents for the treatment of Parkinson's disease and movement disorders associated with Parkinson's disease.

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: ##STR00001##
wherein the variables are as defined herein.

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: ##STR00001##
wherein the variables are as defined herein.

The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R.sup.1, X, Y and R.sup.2 are as defined in the claims.

##STR00001##

An organic EL device includes a first emitting layer and a second emitting layer, in which the first emitting layer contains a first host material, the second emitting layer contains a second host material, the first and the second host material are mutually different, the first emitting layer and the second emitting layer at least contains a compound that emits fluorescence having a main peak wavelength of 500 nm or less, respectively, the compound contained in the first emitting layer and that emits fluorescence having a main peak wavelength of 500 nm or less is the same as or different from the compound contained in the second emitting layer, and a triplet energy T.sub.1(H1) of the first host material and a triplet energy T.sub.1(H2) of the second host material satisfy a numerical formula (Numerical Formula 1),

T.sub.1(H1)>T.sub.1(H2)  (Numerical Formula 1).

An organic electroluminescence device includes an anode, a cathode, a first emitting layer, and a second emitting layer provided between the first emitting layer and the cathode, in which the first emitting layer includes, as a first host material, a first compound that includes at least one group represented by a formula (11) below, the first compound being represented by a formula (1) below, the second emitting layer includes a second compound represented by a formula (2A) below as a second host material, and the first emitting layer is in direct contact with the second emitting layer.

##STR00001##

Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.